Skip to main content
OpenTrials
Completed

NCT Number: NCT04591691

C-myc Biomarker Study for Diabetic Foot Ulcers

This is a multi-center observational cohort study of patients with diabetic foot ulcers (DFU) to develop and validate potential tissue-based biomarkers that predict complete wound healing. Eligible and consented participants will begin standard of care treatment after collection of tissue specimens from the wound's edge. An additional tissue specimen is collected at 4 weeks if clinically indicated. Tissues will be tested for c-myc and phosphorylated glucocorticoid receptor (p-GR) levels using validated protocols at a central laboratory. Participants will be followed weekly for up to 12 weeks or until complete wound healing (whichever occurs first). One final assessment 2 weeks after complete wound healing will occur to confirm healing.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of California - San Francisco, San Francisco, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18 years or older.
  • Clinically diagnosed with diabetes or meeting the American Diabetes Association (ADA) criteria.
  • Foot ulcer of diabetic etiology, with all of the following characteristics:
  • Ulcer size > 0.5 cm2 and < 12 cm2 at least 2 cm from any other ulcer, and
  • Ulcer with Wagner grade 1 or 2 In case of multiple ulcers, select the largest ulcer that meets inclusion criteria.
  • Patients with neuropathic or neuro-ischemic ulcers with adequate circulation to allow healing to the affected extremity as demonstrated by at least 2 of the following within 6 months of Visit 1:
  • Ankle brachial index (ABI) ≥ 0.6 with Doppler Waveforms, or
  • Absolute ankle pressure ≥ 70 mm Hg, or
  • Toe pressure ≥ 40 mmHg, or
  • TcPO2 ≥ 40 mmHg
  • Willingness to comply with standard of care which includes an initial surgical debridement of the wound.

Exclusion criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Patient participating in an interventional clinical trial within 1 month of Visit 1
  • Currently receiving radiation to target area or chemotherapy
  • Participants with Charcot's foot or other foot deformities that prevents adequate targeted ulcer offloading
  • Participant with active severe infection or osteomyelitis at the time of screening
  • History of cancer within last 3 years, other than non-melanoma skin cancer
  • Known or suspected malignancy of current study ulcer
  • Use of adjunctive therapy within previous 30 days
  • Currently receiving medication considered to be systemic glucocorticoids
  • Plan to perform a vascular intervention, such as surgical bypass, angioplasty or stenting, or < 1 month from a prior ipsilateral vascular intervention
  • Any history of concomitant medical condition that, in the opinion of the investigator(s), would compromise the participant's ability to safely complete the study

Treatment and study plan

Primary outcomes

  1. Proportion of participants with complete wound healing by week 12, defined as complete wound closure where there is skin re-epithelialization without drainage or dressing requirements

    Time frame: Up to 12 weeks

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Collaborators

  • Indiana University
  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • Stanford University
  • University of California, San Francisco
  • University of Miami
  • University of Pittsburgh

Registry information

Official study title

Predictive and Diagnostic Biomarkers for Diabetic Foot Ulcers - C-myc and Phosphorylated Glucocorticoid Receptor

Important dates

Study start
2020
Primary completion
2023
Study completion
2023
First posted
Oct 19, 2020
Registry last updated
Jul 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.